已收盤 07-18 16:00:00 美东时间
-0.260
-3.01%
Orion Minerals Limited ( ($AU:ORN) ) just unveiled an announcement. Orion Miner...
07-14 08:37
Orion Group Holdings, Inc. will release its Q2 2025 financial results after market close on July 29, 2025. A conference call and webcast will be held on July 30 at 9:00 a.m. Eastern Time (8:00 a.m. Central Time) to discuss the results. Participants can join via telephone at 844-481-2994 or access the webcast at [Orion Group Holdings, Inc. - Investor Relations].
07-09 11:00
HR Path宣布战略性收购德国公司HORN Payroll Company GmbH,该公司专门从事薪酬外包和临时服务。此次收购是HR Path的一个重大里程...
07-08 15:22
FILA推出全新TORNADO飓风鞋,融合都市户外风格与轻便透气功能,打破通勤与出行场景界限。鞋底采用不规则岩石纹理及上翻橡胶设计,搭配绣线模拟风吹痕迹的鞋身...
07-03 18:15
An announcement from Torrent Pharmaceuticals Ltd ( ($IN:TORNTPHARM) ) is now av...
06-30 12:43
基于COMPASSION-15研究,2024年9月30日,国家药品监督管理局(NMPA)批准了康方生物独立自主研发的PD-1/CTLA-4双特异性抗体开坦尼(卡...
06-24 08:34
Orion Minerals Limited ( ($AU:ORN) ) just unveiled an announcement. Orion Miner...
06-23 08:48
Orion Group Holdings, Inc. (NYSE:ORN) ("Orion" or the "Company"), a leading specialty construction company, today announced new Marine and Concrete awards for a total value of approximately $100 million. In
06-19 19:09
Orion Group Holdings, Inc. has secured approximately $100 million in new Marine and Concrete contracts. The projects include maintenance dredging at the Port of Tampa Bay, the Port Redwing Berth 301 Wharf project, a data center project in Iowa, and several other infrastructure and construction initiatives. Additionally, CEO Travis Boone and General Counsel Chip Earle were honored with prestigious leadership awards for their contributions to the c...
06-19 11:00
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim:维持Metsera(MTSR)"买入"评级,目标价从56美元升至62美元</p> <p>• 摩根大通:维持Avidity Biosciences(RNA)"超配"评级,目标价从57美元升至59美元</
06-11 09:43